The Chronicle9h
Duke professor-led biotech company raises $175 million to advance epigenome editing therapy clinical trials
The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic ...
Peninsula biotech moves from IPO to chopping half its workforce in little more than a year
After a nearly $300 million IPO little more than a year ago, a young Peninsula biotech company will discontinue what had been ...